摘　要：心血管疾病是目前全球首位死亡病因，虽然其发病机制的研究和临床治疗已取得了很大的进展，但死亡率仍居高不下，亟待通过新的方式对其进行科学干预。肠道菌群是人体内数量最多且种类最为复杂的微生物群落，对机体的健康稳态起到重要的作用。菌群失衡可导致包括心血管疾病在内的多种慢性疾病，并形成一个“微生物-肠-心轴”的关系，说明肠道菌群及其代谢产物可能是治疗心血管疾病的潜在生物靶标。本文阐述了“微生物-肠-心轴”与心血管疾病之间的调控机制，并从肠道微生物群的角度提出心血管疾病的预防和治疗策略，以期为临床治疗提供参考。
关键词：肠道菌群；心血管疾病；微生物-肠-心轴；肠道菌群代谢产物；新型冠状病毒
中图分类号：R54　　　　　　文献标志码：A　　　　　DOI：10.3969/j.issn.1007-7146.2025.03.003

Abstract: Cardiovascular disease is currently the leading cause of death in the world, and although great progress has been made in the research and clinical treatment of its pathogenesis, the mortality rate is still high, and new ways of scientific intervention are urgently needed. Intestinal flora is the most numerous and complex microbial community in the human body, which plays an important role in the healthy homeostasis of the body, and its imbalance can lead to a variety of chronic diseases including cardiovascular disease, and form a “microbiome-gut-heart axis” relationship, which speculates that intestinal flora and its metabolites may be potential biological targets for the treatment of cardiovascular disease. This article focuses on the regulatory mechanism between the “microbiome-gut-heart axis” and cardiovascular disease, and proposes the prevention and treatment of cardiovascular diseases from the perspective of intestinal microbiota, in order to provide reference for clinical treatment.
Key words: gut microbes; cardiovascular diseases; microbiome-gut-heart axis; intestinal flora metabolites; novel coronavirus
（Acta Laser Biology Sinica, 2025, 34(3): 214-220）